Patients: Why NH-BMT?
Dr. Liza Bachier discusses the Northside BMT and Multiple Myeloma Programs
National Leader in Blood and Marrow Transplants:
In the top percentage nationally for transplant volumes
Among the Best Allogeneic survival outcome data in the United States (www.nmdp.org), where the actual 2024 one-year survival rate is 82.6%*
Only transplant center in Georgia to collaborate with Dana Farber Cancer Institute’s Innovative Research Partnership: Blood Cancer Research Partnership (BCRP).
The NH–BMT Program meets the criteria of an excellent transplant center.
BMT physician team has completed post-hematology/oncology fellowship training in hematopoietic stem cell transplantation.
Highly trained BMT/leukemia/immunotherapy Team that includes a dedicated BMT health psychologist, social worker, clinical BMT PharmD’s, nutritional services, physical therapy, and chaplain services.
State-of-the-art facilities
Comprehensive quality management program
Among the BEST survival outcomes in United States
ONLY BMT program in the country, and the only BMT program in Georgia, to achieve survival outcomes that significantly exceeded the expected survival rate for allogeneic transplants for the past 16 consecutive reporting cycles (2009-2024). **
BMTGA physicians coordinate pre – post transplant care with your referring physician. Be assured treatment recommendations will be the most current and state-of-the-art.
Access to cutting edge Clinical Trials
Collaboration with Dana-Farber Cancer Institute on Innovative Research Partnership: This groundbreaking Blood Cancer Research Partnership (BCRP), dana-farber.org/BCRP, will bring clinical trial testing of innovative blood cancer therapies to community oncology settings across the country. NH-BMT is one of ten sites who have been selected to participate in this prestigious partnership.
NCI- NCORP: Northside Hospital Cancer Institute and Lewis Cancer and Research Pavilion have partnered with Georgia CORE to participate in NCORP. After a successful first five years, a statewide cancer research consortium has been awarded a six-year grant expected to result in more than $11 million in funding from the National Cancer Institute (NCI) to enroll even more Georgians in important clinical trials.
Patient satisfaction survey for Northside Hospital’s inpatient BMT/Leukemia/ Immunotherapy unit was in the 95 percentile and they were likely to recommend to friends and family.***
* The American Society for Blood and Marrow Transplantation (ASBMT), The Foundation for Cellular Therapy (FACT) and the National Marrow Donor Program (NMDP) are three bone marrow transplant governing organizations that provide patients and family members with detailed information on how to identify an excellent transplant center: outstanding survival outcomes, experienced or trained staff, a comprehensive quality management program, and state-of-the-art facilities.
**For the sixteenth consecutive year (2009-2024), NH-BMT achieved survival outcomes that significantly exceeded the expected range, as reported in the Center for International Blood and Marrow Transplant Research's Final 2024 Transplant Center Specific Survival Report and from reported outcome data from nmdp.org. There were 172 adult and pediatric transplant centers included in the analysis. This survival information includes only patients who received their first allogeneic transplant between January 1, 2020, and December 31, 2022, using unrelated or related donors, and who had reported follow-up. Specific transplant center information can be found at nmdp.org.
***2023 Press Ganey HCAHPS Regulatory Survey